AKBA Akebia Therapeutics, Inc.
$0.66▲ +2.58%
Healthcare
Other
Volume 5.38M
Avg Volume (10D) 10.94M
Key Metrics & Fundamentals
Market Cap
$183.00M
P/E Ratio
–
Div Yield
0.00%
52W Range
0.54 - 3.20
% vs 50 MA
-22.77%
% vs 200 MA
-42.91%
RSI-14
37.7
MACD Histogram
-0.0100
Beta (1Y vs SPY)
1.13
Free Cash Flow
-$554,000
Gross Rev
$49.13M
Gross Profit
$38.70M
EBITDA
-$3.80M
COGS
$10.42M
Operating Exp
$43.09M
Operating Income
-$4.38M
EBIT
-$4.38M
Pretax Income
-$8.84M
Net Income
-$8.91M
EPS (Diluted)
-0.03
Price & Volume History
Loading chart…
Recent News
U.S. Renal Care Presents Analysis of VOICE Trial Demonstrating Favorable Safety Outcomes for Patients Treated with Vadadustat Versus an ESA During a Late-Breaking Session at American Society of Nephrology Kidney Week
GlobeNewswire · Oct 26, 2026 9:20 AM ET
Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum
GlobeNewswire · Oct 7, 2026 8:00 AM ET
Akebia Therapeutics Announces Late-Breaking VOICE Trial Presentation and Posters on Akebia’s Rare Kidney Pipeline at ASN Kidney Week 2026
GlobeNewswire · Oct 6, 2026 8:00 AM ET
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Oct 1, 2026 4:05 PM ET
SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors
GlobeNewswire · Sep 22, 2026 8:00 AM ET
SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development
GlobeNewswire · Sep 15, 2026 8:00 AM ET
Akebia Therapeutics Doses First Patient in Phase 2 Ebribafusp Trial
MT Newswires · Sep 14, 2026 10:13 AM ET
Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases
GlobeNewswire · Sep 14, 2026 8:00 AM ET
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Sep 1, 2026 4:05 PM ET
Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston
GlobeNewswire · Sep 1, 2026 8:00 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See AKBA's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.